FDA grants fast track designation to AskBio’s AB-1005 for PD
Bayer and Asklepios BioPharmaceutical (AskBio) have announced FDA fast track designation for AB-1005, a gene therapy for PD.
Bayer and Asklepios BioPharmaceutical (AskBio) have announced FDA fast track designation for AB-1005, a gene therapy for PD.
What's Your Reaction?
